Status:
UNKNOWN
Safety and Feasibility of Using Epicall for Monitoring Pre-seizure Biomarkers
Lead Sponsor:
Epicall LTD
Conditions:
Seizure
Eligibility:
All Genders
1-18 years
Brief Summary
Epilepsy is a syndrome of episodic brain dysfunction characterized by recurrent seemingly unpredictable spontaneous seizures. The occurrence of the seizure in patients without any forewarning is the m...
Eligibility Criteria
Inclusion
- Children age 1 year -18 years old.
- Hospitalized patient who is diagnosed with epilepsy.
- Patient's parents/care giver able to comprehend and give informed consent for participation in this study.
- Patient's parents/care giver must commit to both screening and monitoring visits.
- Patient's parents/care giver must sign the Informed Consent Form.
Exclusion
- Patient with any infection / abscess / bleeding / blister / crack / edema / fissure / ulcer / pain in monitoring electrode area
- General weakness.
- Patient's parents/care giver objects to the study protocol.
- Concurrent participation in any other clinical study.
- Physician objection.
Key Trial Info
Start Date :
November 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01436695
Start Date
November 1 2011
Last Update
September 20 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asaf Harofeh Medical Center
Zrifin, Israel